News & Updates

Use of tenofovir disoproxil fumarate (TDF) for ≥24 months increases the risk of fracture in older patients with chronic hepatitis B (CHB), reports a study.

Post-exposure prophylaxis with the probiotic Lacticaseibacillus rhamnosus GG (LGG) led to prolonged time to COVID-19 infection, reduced incidence of symptoms, and gut microbiome changes, but not overall incidence, a study suggests.

Patients with chronic hepatitis B (CHB) who has undergone long-term treatment with tenofovir alafenamide (TAF) achieve high rates of viral suppression comparable to those of tenofovir disoproxil fumarate (TDF; or TDF switched to TAF) with favourable renal and bone safety, results of a study have shown.